Nirsevimab
(Redirected from Beyfortus)
Nirsevimab is a monoclonal antibody designed for the prevention of respiratory syncytial virus (RSV) infections in infants and young children. It is specifically engineered to provide passive immunity by targeting the RSV fusion (F) protein, which is essential for the virus's ability to infect host cells.
Mechanism of Action
Nirsevimab works by binding to the RSV F protein, thereby neutralizing the virus and preventing it from entering and infecting human cells. This mechanism is similar to that of other monoclonal antibodies used in infectious disease prevention, such as Palivizumab, but Nirsevimab has been optimized for a longer half-life, allowing for less frequent dosing.
Clinical Development
Nirsevimab has undergone several phases of clinical trials to evaluate its safety, efficacy, and pharmacokinetics. These trials have demonstrated that Nirsevimab is effective in reducing the incidence of RSV-related hospitalizations and medical visits in infants.
Indications
Nirsevimab is indicated for the prevention of RSV infections in infants and young children, particularly those who are at high risk for severe RSV disease, such as premature infants, infants with congenital heart disease, and those with chronic lung disease.
Administration
Nirsevimab is administered via intramuscular injection. The dosing schedule is designed to provide protection throughout the RSV season, which typically lasts from late fall to early spring in temperate climates.
Side Effects
Common side effects of Nirsevimab include injection site reactions, fever, and rash. Serious adverse events are rare but may include hypersensitivity reactions.
Comparison with Other Treatments
Nirsevimab offers several advantages over existing RSV prophylactic treatments, such as Palivizumab, including a longer duration of action and potentially fewer injections required over the RSV season.
Related Pages
- Respiratory syncytial virus
- Monoclonal antibody
- Palivizumab
- Congenital heart disease
- Chronic lung disease
See Also
References
External Links
-
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD